Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P10636 (
tau protein
)
5,110
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Decreased levels of soluble
ubiquitin carboxy-terminal hydrolase L1
(
UCHL1
) have been reported in the brains of sporadic Alzheimer's disease (AD) patients, and the introduction of
UCHL1
rescued the synaptic and cognitive function of AD model mice. Obviously, a reduction in the levels of
UCHL1
may play a role in the pathogenesis of AD. However, the mechanisms underlying the regulation of
UCHL1
levels in AD have not been fully elucidated. MicroRNAs (miRs) have been shown to participate in the process of AD. In our study, we discovered that microRNA-922 decreased the levels of
UCHL1
. Neurofibrillary tangles (NFTs) mainly consisting of the hyperphosphorylated
microtubule-associated protein tau
are the defining pathological features of AD. In the present study, we found the levels of
UCHL1
affected the levels of phosphorylated tau: the phosphorylated tau levels increased after knockdown of
UCHL1
expression, and the phosphorylated tau levels decreased when
UCHL1
was overexpressed. Furthermore, overexpression of microRNA-922 increased the phosphorylated tau levels. In conclusion, miR-922 increasing the levels of phosphorylated tau by regulating
UCHL1
levels contributed to the pathogenesis of AD. Our study partly explained one of the mechanisms underlying the downregulation of
UCHL1
levels in AD patients and could enrich the content of tau pathology in the pathogenesis of AD.
...
PMID:MicroRNA-922 promotes tau phosphorylation by downregulating ubiquitin carboxy-terminal hydrolase L1 (UCHL1) expression in the pathogenesis of Alzheimer's disease. 2495 Jan 20
In conditions of proteasomal impairment, the damaged or misfolded proteins, collectively known as aggresome, can accumulate in the perinuclear space and be subsequently eliminated by autophagy. Abnormal aggregation of
microtubule-associated protein tau
in the cytoplasm is a common neuropathological feature of tauopathies. The deficiency in
ubiquitin carboxy-terminal hydrolase L1
(
UCH-L1
), a proteasomal deubiquitinating enzyme, is closely related to tau aggregation; however, the associated mechanisms remain unclear. Here, we showed that
UCH-L1
inhibition interrupts proteasomal impairment-induced tau aggresome formation. By reducing the production of lysine (K63)-linked ubiquitin chains,
UCH-L1
inhibition decreases HDAC6 deacetylase activity and attenuates the interaction of HDAC6 and
tau protein
, finally leading to tau aggresome formation impairment. All these results indicated that
UCH-L1
plays a key role in the process of tau aggresome formation by regulating HDAC6 deacetylase activity and implied that
UCH-L1
may act as a signaling molecule to coordinate the effects of the ubiquitin-proteasome system and the autophagy-lysosome pathway, which mediate protein aggregates degradation in the cytoplasm.
...
PMID:UCH-L1 Inhibition Suppresses tau Aggresome Formation during Proteasomal Impairment. 2854 Jun 57
Transcriptome analysis has identified a plethora of long non-coding RNAs (lncRNAs) expressed in the human brain and associated with neurological diseases. However, whether lncRNAs expression levels correlate with Parkinson's disease (PD) pathogenesis remains unknown. Herein, we show that a number of lncRNA genes encompassing transcriptional units in close proximity to PD-linked protein-coding genes, including
SNCA
,
LRRK2
,
PINK1
,
DJ-1
,
UCH-L1
,
MAPT
and
GBA1
, are expressed in human dopaminergic cells and post-mortem material, such as cortex,
Substantia Nigra
and cerebellum. Interestingly, these lncRNAs are upregulated during neuronal differentiation of SH-SY5Y cells and of dopaminergic neurons generated from human fibroblast-derived induced pluripotent stem cells. Importantly, six lncRNAs are found under-expressed in the nigra and three in the cerebellum of PD patients compared to controls. Simultaneously,
SNCA
mRNA levels are increased in the nigra, while
LRRK2
and
PINK1
mRNA levels are decreased both in the nigra and the cerebellum of PD subjects compared to controls, indicating a possible correlation between the expression profile of the respective lncRNAs with their adjacent coding genes. Interestingly, all dysregulated lncRNAs are also detected in human peripheral blood mononuclear cells and four of them in exosomes derived from human cerebrospinal fluid, providing initial evidence for their potential use as diagnostic tools for PD. Our data raise the intriguing possibility that these lncRNAs may be involved in disease pathogenesis by regulating their neighboring PD-associated genes and may thus represent novel targets for the diagnosis and/or treatment of PD or related diseases.
...
PMID:Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson's Disease Patients. 3085 99